Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743637 | 0.85 | PLA2G4B (0.49) | MTNR1AMTNR1BCTBP2 | |
| SCHEMBL28035509 | 0.84 | SLC7A5 (0.52) | SLC7A5ALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL18920453 | 0.82 | SLC7A5 (0.54) | SLC7A5ALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL378705 | 0.81 | SMN1; SMN2 (0.61) | SLC7A5MTNR1AMTNR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL31249652 | 0.81 | SMN1; SMN2 (0.61) | SLC7A5MTNR1AMTNR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL2767480 | 0.80 | SMN1; SMN2 (0.53) | SLC7A5ALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL13803187 | 0.80 | TSHR (0.44) | MTNR1AMTNR1BSMN1; SMN2TSHRGAA | |
| SCHEMBL758042 | 0.80 | TSHR (0.44) | MTNR1AMTNR1BSMN1; SMN2TSHRGAA | |
| SCHEMBL12327116 | 0.79 | MAPK1 (0.47) | MTNR1AMTNR1BALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL12400239 | 0.79 | SLC7A5 (0.68) | SLC7A5ALDH1A1SMN1; SMN2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | GFPT1, GLS2, GLS | SLC7A5 203/4885MTNR1A 3487/4885MTNR1B 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.